Celyad Oncology Reports €24.8 Million Net Loss for 2025 and Implements Cost-Saving Measures to Extend Financial Runway

Celyad Oncology has released its financial results for the full year ending December 31, 2025, along with updates on its business operations. The company reported a net loss of €24.8 million for the year, compared to a net loss of €26.3 million in 2024. Cash and cash equivalents stood at €12.7 million as of December 31, 2025, down from €19.2 million at the end of the previous year.

The company highlighted several key developments during 2025. It continued to focus on advancing its pipeline of CAR-T cell therapies targeting cancer treatment and announced progress in preclinical research efforts. Celyad also noted that it had implemented cost-saving measures throughout the year to extend its financial runway into mid-2026. Additionally, the company stated that it remains committed to exploring strategic options to support its long-term growth and development initiatives.

Further details regarding Celyad’s operational updates and financial performance can be found in their official report published online.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 2, 2026

Author

GOAI